Roche's Genentech is pairing up with Novartis to split the ex-U.S. rights to an Ophthotech eye drug, opting into an agreement that could be worth more than $1 billion.
An affiliate of Hong Kong-listed Lee's Pharmaceutical Holdings has licensed the TG02 oncology treatment developed by California-based Tragara Pharmaceuticals, the companies said in a statement.
Array BioPharma, hunting for partners after Novartis walked away from a pair of cancer projects, has linked up with Pierre Fabre to co-develop the treatments in an agreement worth up to $455 million.
Indonesia's Kalbe Farma has signed a deal with South Korea's Genexine in which it will invest $9.1 million to develop biopharmaceutical products and create an R&D laboratory in Indonesia to research the hormone erythropoietin, which helps produce red blood cells, according to a report by the Nikkei Asian Review.
Genomics England, the company set up by the country's Department of Health to sequence 100,000 human genomes, has brought in China's WuXi NextCODE as the first of its "clinical interpretation partners," according to a report by state-owned news agency Xinhua.
A British consortium plans to spend $1.5 billion to bring 11 NHS-related facilities to India, according to a report by the Economic Times.
GE Healthcare will work with Oregon Health & Science University to develop collaborative research programs in cardiovascular medicine, imaging and big data research. They expect to address essential questions about biology and medicine through the combination of the clinical expertise of OHSU and the technological facility of GE Healthcare.
China's WuXi PharmaTech and U.S.-based Eli Lilly plan to develop a candidate to lower cardiovascular risk in patients with dyslipidemia in China that will see the local firm carry the load on development regulatory approval and manufacturing, while the Indianapolis headquarter multinational focuses on sales and marketing.
With an eye on an "emergent global health concern," GeneOne Life Science teamed up with the Walter Reed Army Institute of Research this week to usher its vaccine for Middle East respiratory syndrome (MERS) into a first-in-human trial at the institute.
The race is on to develop U.S. sources for a material necessary to create the most widely used radioisotope in medical diagnostic imaging. Now GE Healthcare and startup Shine Technologies have disclosed that they have successfully used GE's existing tech to create the common medical radioisotope technetium-99m (Tc‑99m) from molybdenum-99 (Mo-99) produced by Shine.